Know Cancer

forgot password

An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma

16 Years
Open (Enrolling)

Thank you

Trial Information

An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma



- Determine whether measurements of fludeoxyglucose (FDG) positron emission tomography
(PET)/CT imaging can accurately predict disease-free survival of patients with soft
tissue sarcoma who are receiving neoadjuvant chemotherapy.


- Correlate histological response to neoadjuvant chemotherapy for soft tissue sarcomas
with FDG-PET/CT imaging findings.


- Determine the changes in FDG-PET/CT imaging over time as each course of chemotherapy is

OUTLINE: Patients receive 1 of 2 standard chemotherapy regimens:

- Preferred regimen: Patients receive pegylated doxorubicin HCl liposome IV on day 1,
ifosfamide IV continuously on days 1-6, and pegfilgrastim subcutaneously (SC) on day 8.
Treatment repeats every 28 days for up to 4 courses in the absence of disease
progression or unacceptable toxicity.

- Alternative regimen: Patients receive doxorubicin hydrochloride IV continuously on days
1-7. Patients also receive ifosfamide and pegfilgrastim as in the preferred regimen.
Treatment repeats every 28 days for up to 4 courses in the absence of disease
progression or unacceptable toxicity.

All patients undergo a fludeoxyglucose positron emission tomography/CT scan at baseline,
after course 1, and after completion of chemotherapy. Patients undergo surgery within 4-6
weeks after completion of chemotherapy.

After completion of study treatment and surgery, patients are followed every 6 months for 5

PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study.

Inclusion Criteria:

- Patients must have histologically confirmed, high grade, soft tissue sarcoma

- malignant fibrous histiocytoma,

- liposarcoma,

- fibrosarcoma,

- leiomyosarcoma,

- synovial carcinoma,

- malignant peripheral nerve sheath tumor (MPNST),

- epithelioid sarcoma, and

- sarcomas-not otherwise specified.

NOTE: Ewings sarcoma, primitive neuroectodermal tumor, extraskeletal, osteosarcoma,
extraskeletal chondrosarcoma, alveolar soft part sarcoma, rhabdomyosarcoma,
carcinosarcoma, Kaposi's sarcoma, angiosarcoma, and mesothelioma patients are ineligible
for this study.

- Measurable disease using traditional cross section measurements with the primary
site's largest diameter > 5 centimeters by positron emission tomography/computated
tomography (PET/CT), CT or magnetic resonance imaging (MRI) scan. Patients with
either localized (primary or locally recurrent) or metastatic disease at presentation
are eligible for study if they are to receive neoadjuvant treatment prior to excision
of the primary (stage IIC, III, IVA, IVB.)

- Age ≥ 16 years, Karnofsky ≥ 70%

- Adequate organ function for receiving chemotherapy as determined by the treating

- Women of childbearing potential and sexually active males are required to use an
effective method of contraception (ie, a hormonal contraceptive, intra-uterine
device, diaphragm with spermicide, condom with spermicide, or abstinence) during the

Exclusion Criteria:

- Previous treatment with chemotherapy or radiation therapy

- Females known to be pregnant or breast-feeding are excluded because PET/CT scan in
pregnant women is not FDA approved.

- Serious concomitant systemic disorders (eg, active infection) that, in the opinion of
the investigator, would compromise the safety of the patient or compromise the
patient's ability to complete the study. Patients with PET-CT as an indicator of
disease survival in soft tissue sarcoma untreated or symptomatic CNS metastases or
uncontrolled diabetes will not be eligible.

Patient must give written informed consent indicating the investigational nature of the
study and its potential risks.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Disease-free survival

Outcome Description:

Compare changes in baseline and follow-up fludeoxyglucose (FDG) positron emission tomography (PET)/CT imaging with disease-free survival by peak SUV and max SUV calculations. Changes in baseline and follow-up PET/CT, based on max SUV calculations, will be compared with disease free survival. Disease free survival will be measured in months from the time of study enrollment until the time that disease recurrence/relapse/progression is recorded.

Outcome Time Frame:

Baseline through Survival Event

Safety Issue:


Principal Investigator

Edward Cheng, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota


United States: Institutional Review Board

Study ID:




Start Date:

April 2006

Completion Date:

April 2014

Related Keywords:

  • Sarcoma
  • soft tissue sarcoma
  • Malignant fibrous histiocytoma
  • Liposarcoma
  • Fibrosarcoma
  • Leiomyosarcoma
  • Synovial sarcoma
  • Malignant peripheral nerve sheath tumor (MPNST)
  • Epithelioid sarcoma
  • Sarcoma



Sinai Hospital of Baltimore Baltimore, Maryland  21225
Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota  55455